The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA )
5 Jun 2022
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significanc...
Dr Julie Gralow- Chief Medical Officer, ASCO
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )
5 Jun 2022
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosf...
Dr Julie Gralow- Chief Medical Officer, ASCO
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )
5 Jun 2022
Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for...
Dr Martin McCabe- University of Manchester, Manchester, England
Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Martin McCabe- University of Manchester, Manchester, England )
5 Jun 2022
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )
5 Jun 2022
(RVd) ± , stem cell transplantation and R maintenance shows significance for new...
Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA
(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory ewing...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 D...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022
Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides bene...
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-defic...
Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )
5 Jun 2022
Latest in testing and diagnostics in exon 20 NSCLC
Dr Antonio Passaro and Prof Paul Hofman
Latest in testing and diagnostics in exon 20 NSCLC ( Dr Antonio Passaro and Prof Paul Hofman )
4 Jun 2022

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation